A company I'm watching, IDRA, is similar to CTIX in a way that both have a drug for cancer and psoriasis. Although its pipeline is nowhere as strong as CTIX, its market cap has always been higher. But its stock hit a 52 week low today despite having Baker Brothers on the board, trading on the Nasdaq, and a 40% institutional ownership. I'm glad Leo didn't uplist just for the sake of it. All the temporary gain will disappear if your pipeline isn't progressing. This goes to show that trial data trump everything, and we'll have not one (P), not two (B-OM), but three (B-ABSSSI) coming in the next 6-12 months.